Contineum Therapeutics, Inc. (CTNM) — Financial statements
Income statement, balance sheet, and cash flow for Contineum Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 50 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.26 | 0.00↓100.0% | 0.33 | 0.00 | |
| Gross Profit | 0.00↑100.0% | -0.26↓100.5% | 50↑15297.6% | -0.33 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 52↑35.0% | 38↑38.3% | 28↑63.4% | 17↓24.4% | 22 | |
| General & Administrative Expenses | 17 | 0.00↓100.0% | 6 | 0.00↓100.0% | 6 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 17↑32.6% | 12↑97.3% | 6↑15.0% | 5↓12.6% | 6 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 32 | 0.00↑100.0% | -0.09 | |
| Operating Expenses | 68↑34.4% | 51↓23.4% | 66↑195.1% | 22↓21.8% | 29 | |
| Total Costs & Expenses | 68↑33.7% | 51↓23.0% | 66↑190.8% | 23↓20.7% | 29 | |
| Operating Results | ||||||
| Operating Income | -68↓33.7% | -51↓216.6% | -16↑29.2% | -23↑20.7% | -29 | |
| Depreciation & Amortization | 0.32↑25.2% | 0.26↑32.3% | 0.20↓40.7% | 0.33↑1.2% | 0.33 | |
| EBITDA | -68↓61.3% | -42↓278.2% | 24↑200.2% | -24↑16.9% | -28 | |
| EBIT | -68↓61.1% | -42↓280.8% | 23↑198.0% | -24↑16.8% | -29 | |
| Interest & Other Income | ||||||
| Net Interest Income | 8↓7.4% | 9↑102.5% | 4↑1079.1% | 0.37↑246.3% | -0.26 | |
| Interest Income | 8↓7.4% | 9↑93.3% | 5↑505.3% | 0.76↑888.3% | 0.08 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 0.21↓46.4% | 0.39↑16.9% | 0.33 | |
| Non-Operating Income | 0.00↑100.0% | -9↑78.1% | -39↓3545.9% | 1↑5104.5% | 0.02 | |
| Other Income / Expenses | 8↓6.4% | 9↓78.0% | 39↑2660.1% | -2↓333.1% | -0.35 | |
| Income Before Tax | -60↓41.9% | -42↓282.4% | 23↑195.5% | -24↑16.4% | -29 | |
| Income Tax Expense | 0.00 | 0.00↓100.0% | 0.45 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -60↓41.9% | -42↓286.0% | 23↑193.7% | -24↑16.4% | -29 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -60↓41.9% | -42↓286.0% | 23↑193.7% | -24↑16.4% | -29 | |
| Bottom-Line Net Income | -60↓41.9% | -42↓286.0% | 23↑193.7% | -24↑16.4% | -29 | |
| EPS (Basic) | -2.17↓33.1% | -1.63↓1353.8% | 0.13↑113.4% | -0.97↑15.7% | -1.15 | |
| EPS (Diluted) | -2.17↓33.1% | -1.63↓1353.8% | 0.13↑113.4% | -0.97↑15.7% | -1.15 | |
| Weighted Average Shares | 28↑7.1% | 26↑2.9% | 25↑0.0% | 25↑0.0% | 25 | |
| Weighted Average Diluted Shares | 28↑7.1% | 26↑2.9% | 25↑0.0% | 25↑0.0% | 25 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.